CA-ANDERSEN-GLOBAL
10.6.2022 12:17:06 CEST | Business Wire | Pressemeddelelse
Andersen Global fortsætter sin ekspansion på det nordiske marked gennem samarbejdsaftaler med det danske advokatfirma Bachmann/Partners og det finske advokatfirma I&O Partners. Med udgangspunkt i de eksisterende samarbejdende virksomheder Hellström Law og Unum i Sverige og Braekhus i Norge, styrker disse tilføjelser organisationens omfattende og integrerede skattemæssige og juridiske dækning i regionen.
Med kontorer i København og Aarhus tilbyder Bachmann/Partners en bred vifte af tjenester, herunder skattestrid og rådgivning, moms, punktafgifter, strafferetlig skatteret, arve- og ejendomsplanlægning for private og familieejede virksomheder med stor formue, international skatte- og erhvervsret. Bachmann/Partners, som er anerkendt af The Legal 500 som en konkurrencedygtig virksomhed i regionen, blev grundlagt i 2016 af ledende partner Christian Bachmann og leverer tjenester til lokale og internationale kunder.
”Vi har gennem årene opbygget vores omdømme på baggrund af vores store kendskab til dansk erhvervsliv, især vores specialisering i alle skatteretlige forhold”, siger Christian. ”Vi ser frem til at arbejde sammen med medlemsvirksomhederne og de samarbejdende virksomheder i Andersen Global, samtidig med at vi fastholder en konkurrencefordel på markedet og leverer omfattende løsninger til kunder globalt”.
I&O Partners blev grundlagt i 2015 og bistår kunder inden for områder som bank og finans, virksomhedsrådgivning, erhverv, tvistbilæggelse, ansættelse, fusioner og opkøb, IP-teknologi, omstrukturering og privat formue. Under ledelse af ledende partner Andrei Aganimov arbejder virksomhedens team på mere end 16 fagfolk tæt sammen med nationale og internationale virksomheder såvel som private kunder.
”Virksomheden er vokset ret hurtigt siden vores grundlæggelse for næsten syv år siden, og vores samarbejde med Andersen Global er næste skridt i vores vækst og udvikling”, siger Andrei. ”Vores samarbejde positionerer os til at udnytte den kollektive styrke i en global organisation, overgå kundernes forventninger og levere problemfri service”.
”Bachmann/Partners og I&O Partners deler et stærkt engagement i klassens bedste service og en passion for forvaltning og gennemsigtighed”, siger Andersen Globals bestyrelsesformand og CEO Mark Vorsatz. ”Deres teams vil være et stort aktiv til at imødekomme vores kunders voksende behov og vil arbejde synergistisk med medlemsvirksomhederne og de samarbejdende virksomheder i Andersen Global, samtidig med at vi fortsætter med at udbygge vores kapacitet i Nordeuropa”.
Andersen Global er en international sammenslutning af juridisk adskilte, uafhængige medlemsfirmaer, bestående af skatte- og juraeksperter i hele verden. Andersen Global blev stiftet af den amerikanske medlemsvirksomhed Andersen Tax LLC i 2013 og Andersen Global har nu over 11.000 fagfolk globalt og er repræsenteret på mere end 360 lokaliteter via sine medlemsvirksomheder og samarbejdende virksomheder.
Originalsprogsudgaven af denne bekendtgørelse er den officielle, autoriserede version. Oversættelserne er kun tænkt som en hjælp og bør sammenholdes med kildesprogsteksten, der som den eneste er juridisk bindende.
Se kildeudgaven på businesswire.com: https://www.businesswire.com/news/home/20220609005325/da/
Information om Business Wire
Følg pressemeddelelser fra Business Wire
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra Business Wire
Rigaku and Tohoku University Establish a New Research Institute for X-Ray Metrology28.8.2026 16:00:00 CEST | Press release
Rigaku Corporation, a group company of Rigaku Holdings and a global solutions partner for X-ray analytical systems (Head Office: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), and Tohoku University (Sendai, Miyagi; President: Teiji Tominaga; “Tohoku University”) have established the Rigaku-Tohoku University Co-Creation Research Institute for X-ray Metrology: Beyond The Limits (the “Institute”) at Tohoku University on August 1, 2026. The Institute will advance X-ray metrology technology, develop new metrology methods, and foster the next generation of researchers through an initial three-year collaboration, with the possibility of extension based on its achievements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828688510/en/ Inside the Institute As semiconductors become smaller, more multilayered, and incorporate a wider range of materials, manufacturing processes are becoming increasingly complex. X-ray me
BLK: Portfolio Company of Enry’s Island S.p.A., Lists on Euronext Dublin28.8.2026 15:34:00 CEST | Press release
Enry’s Island S.p.A. (WBAG:EIOS), an international venture builder with headquarters in the Tremiti Islands and the Metaverse, announces that BLK Global PLC, one of the portfolio companies within its ecosystem, has successfully completed its admission to trading on Euronext Access Dublin. Trading in the company’s shares commenced on Friday, July 31, 2026, under ticker BLKX and ISIN GB00BPSKS130. BLK was one of the thousands of applications received by Enry’s Island which, following an assessment process based on the Enry’s Model, was selected for a one-year incubation and acceleration programme. The programme supported the company through its subsequent growth stages, ultimately leading to its current stock market listing. Alessandro Pacciana, Investor Relations Manager of Enry’s Island S.p.A., said: “BLK’s listing is the second stock market listing in two years among Enry’s Island’s portfolio companies, while Enry’s Island itself is the world’s first listed venture builder. We are pro
Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 11:00:00 CEST | Press release
Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026 The approval is based on data from the Phase 3 RISE-PD trial where Hopledo® demonstrated a significant increase in Good ON time compared with immediate-release LD/CD with fewer daily doses and a comparable safety profile Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely
MTG-I2 Safely in Orbit, Unlocking Faster and Sharper Weather Monitoring Across Europe28.8.2026 10:16:00 CEST | Press release
The Meteosat Third Generation Imager 2 satellite (MTG-I2) has successfully passed its first critical post-launch milestones, completing the first full Meteosat Third Generation constellation in orbit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828243790/en/ Credit: Arianespace livestream The imager satellite MTG-I2 is safely in orbit and operating as expected following its successful launch yesterday at 22:11 CEST on board an Ariane 6 rocket from Europe’s Spaceport in French Guiana. Our teams have established communication with the spacecraft, which has also deployed its solar panels to ensure its autonomous production of energy. MTG-I2 is in perfect shape to start its Launch and Early Operations Phase that will bring it to a higher orbit, 36 000km above Earth over the following two weeks, where a longer period of calibration and validation of its instruments will begin. This summer’s extreme weather and wildfires hav
New Daiichi Sankyo Data Underscore the Effect of Bempedoic Acid in the Real-World Management of Dyslipidemia and Cardiovascular risk28.8.2026 10:00:00 CEST | Press release
Analyses from the multinational MILOS study show that LDL-C reductions achieved with up to one year of treatment with bempedoic acid-containing therapies translate to a 17.1% relative reduction and a 4.8% absolute reduction in predicted 10-year cardiovascular risk.1 Real-world data demonstrated clinically relevant mean LDL-C reductions of at least 24.9%, regardless of patient gender or glycaemic status, after one year of follow-up.2,3 Findings presented at ESC Congress 2026 reinforce the clinical value of bempedoic acid in routine clinical practice, and demonstrate the continued investment of Daiichi Sankyo in addressing outstanding unmet needs in cardiovascular disease (CVD). Daiichi Sankyo (TSE:4568) today announced new results from the MILOS study that demonstrate the real-world impact of bempedoic acid administered either alone or as a fixed-dose combination with ezetimibe, in the management of dyslipidaemia. Presented at the European Society of Cardiology Congress 2026 in Munich,
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.
Besøg vores nyhedsrum